http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
S-505 The effect of beraprost to treat hemodialysis access failure
( Misun Kim ),( Hyunjoo Oh ),( Ji Ung Kim ),( Hyunwoo Kim ) 대한내과학회 2016 대한내과학회 추계학술발표논문집 Vol.2016 No.1
Hemodialysis vascular access dysfunction is a major cause of morbidity and hospitalization in the hemodialysis patients. The major cause of hemodialysis vascular access dysfunction is venous stenosis as a result of neointimal hyperplasia. Although several studies suggest a role for antiplatelet agents in the prevention of hemodialysis vascular access failure, it has not been complete. It has been reported that prostaglandin I2 has pleiotropic effects including antiplatelet, vasodilating, anti-inflammatory and anti-atherogenic properties. In addition, several studies have shown that prostaglandin I2 can inhibit the neointimal formation generated after vascular injury. The purpose of this study was to research the effects of beraprost sodium, an oral synthetic analog of prostaglandin I2 on vascular access patency in hemodialysis patients with primary hemodialysis vascular access failure. Forty-nine patients with end stage renal disease on hemodialysis were prospectively chosen for this study. Twenty-three patients were assigned to be treated with 120 μg/day of beraprost sodium and the other patients (n=26) were assigned to a control group. The primary outcome was secondary vascular access failure. After median follow-up of 3.3 years, the secondary vascular access failure was detected in twelve patients (58%) in control group and four patients (17%) in beraprost sodium group, respectively (Figure 1, p=0.014). Analysis of covariables indicated that this effect occurred principally as a result of beraprost sodium administration. No life-threatening adverse event or severe bleeding was recorded in both groups. Our data indicated that oral prostaglandin I2 analog is effective and safe for the prevention of secondary vascular access failure in hemodialysis patients with primary vascular access failure.
Flowering and Fruit Characteristics of Dragon Fruit (Hylocereus sp.)
Misun Kim,Seong-Cheol Kim,Seung Jong Chun,Eun-Young Song,Chan Kyu Lim 한국국제농업개발학회 2011 韓國國際農業開發學會誌 Vol.23 No.4
연구는 베트남에서 도입된 두 계통(Hylocereus spp)의 용과에 대하여 개화, 착과율 및 과실 특성을 조사하였다. H. polyrhizus(적색 계)의 H. undatus(백색계)의 개화시작은 각각 7월 9일과 7월20일이었다. 주된 개화시기는 백색계는 8월 하순~9월 상순(69%),H. polyrhizus는 8월 상순~하순(52%)이었다. 두 계통의 최종 개화기는 10월 상순이었다. 착과율은 H. polyrhizus가 45.5%로 90.4%인 H. undatus보다 낮게 나타났다. H. undatus의 평균과중은 301.2g으로 H. polyrhizus보다 1.3배 무거웠다. H. polyrhizus의 총가용성고형물은 12.6 °Brix로 H. undatus(10.7 °Brix)보다 높았으며, 특히 8월초에 개화된 것이 13.0 °Brix로 나타났다. 계통에 따른 산함량 차이는 미미하였다. This study was carried out to investigate the flowering and fruit characteristics of two types of dragon fruit (Hylocereus spp) introduced from Vietnam. The first flowering dates of H. polyrhizus (with red flesh) and H. undatus (with white flesh) were July 9 and July 20, respectively. The major flowering periods were from late August to early September (69%) in H. undatus and early to mid August (52%) in H. polyrhizus. Both dragon fruits have early October as their last flowering date. Fruit set rate of H. polyrhizus was 45.5%, while H. undatus indicated 90.4%. The average weight of fruit of H. undatus was 301.2g and 1.3 times heavier than that of H. polyrhizus (237.4 g). Total soluble solids (TSS) content in H. polyrhizus was 12.6 °Brix which is higher than H. undatus at 10.7 °Brix. This is especially true with plants that flowered in early August (13.0 °Brix). There were little differences in their organic acid contents.
Kim Misun,Heo Sang Taek,Lee Jaechun,Lee Jong Hoo,Kim Miok,Kim Changhwan,Seong Gil Myeong,Kang Myeong Jin,Yoo Jeong Rae 대한감염학회 2024 Infection and Chemotherapy Vol.56 No.1
Background The distribution of species and characteristics of non-tuberculous mycobacteria (NTM) differ, and surveillance data for changes in antimicrobial susceptibilities of NTM is insufficient. This study analyzed the changes in antimicrobial susceptibility trends across NTM species and assessed the appropriateness of empirical antimicrobial drugs for NTM. Materials and Methods We retrospectively analyzed the clinical characteristics, including demographics, distribution of NTM species, antimicrobial drug susceptibilities, and outcomes, at a teaching hospital in Jeju Island from 2009 - 2022. Results Overall, 342 patients were included in the analysis; 93.0% were classified into the pulmonary group (PG) and 7.0% into the extrapulmonary group (EPG). The isolation rate of Mycobacterium avium was significantly higher in PG (36.8% vs. 0%, P = 0.001), while that of Mycobacterium fortuitum was significantly higher in EPG (4.5% vs. 31.3%, P = 0.001). The antimicrobial susceptibility rate is higher against clarithromycin (89.9%) and amikacin (83.3%) and lower against rifampin (54.7%) and ethambutol (28.1%). The susceptibility rate to clarithromycin was over 80%, but those to rifampin and ethambutol showed decreasing annual trends. Of the 162 patients who received empirical antimicrobial therapy, actual antimicrobial susceptibility rates were high (90.1%) using empirical macrolide, and relatively low using ethambutol and rifampin (28.0% and 58.8%, respectively). Conclusion This is the first study of analysis of the distribution, baseline characteristics, and antimicrobial susceptibility of isolated NTM species in pulmonary and extrapulmonary patients in Jeju Island over 10 years. Policies that continuously monitor changes in susceptibility rate are required to ensure effective treatment strategies. Background The distribution of species and characteristics of non-tuberculous mycobacteria (NTM) differ, and surveillance data for changes in antimicrobial susceptibilities of NTM is insufficient. This study analyzed the changes in antimicrobial susceptibility trends across NTM species and assessed the appropriateness of empirical antimicrobial drugs for NTM. Materials and Methods We retrospectively analyzed the clinical characteristics, including demographics, distribution of NTM species, antimicrobial drug susceptibilities, and outcomes, at a teaching hospital in Jeju Island from 2009 - 2022. Results Overall, 342 patients were included in the analysis; 93.0% were classified into the pulmonary group (PG) and 7.0% into the extrapulmonary group (EPG). The isolation rate of Mycobacterium avium was significantly higher in PG (36.8% vs. 0%, P = 0.001), while that of Mycobacterium fortuitum was significantly higher in EPG (4.5% vs. 31.3%, P = 0.001). The antimicrobial susceptibility rate is higher against clarithromycin (89.9%) and amikacin (83.3%) and lower against rifampin (54.7%) and ethambutol (28.1%). The susceptibility rate to clarithromycin was over 80%, but those to rifampin and ethambutol showed decreasing annual trends. Of the 162 patients who received empirical antimicrobial therapy, actual antimicrobial susceptibility rates were high (90.1%) using empirical macrolide, and relatively low using ethambutol and rifampin (28.0% and 58.8%, respectively). Conclusion This is the first study of analysis of the distribution, baseline characteristics, and antimicrobial susceptibility of isolated NTM species in pulmonary and extrapulmonary patients in Jeju Island over 10 years. Policies that continuously monitor changes in susceptibility rate are required to ensure effective treatment strategies.